REQUEST A DEMO
Total
USD $0.00
Search more companies

Korea Pharma Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Korea Pharma Co.,Ltd. Profile Updated: October 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the manufacture and sale of medicinal products. The Company s main products include digestive system solvents, antidepressants, blood circulation agents, antidementia drugs, schizophrenia medicines and others. The Company was established on December 24, 1985. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on August 10, 2020.

Headquarters
87, Jeyakgongdan 3-Gil, Hyangnam-Eup
Hwaseong; Gyeonggi;

Contact Details: Purchase the Korea Pharma Co.,Ltd. report to view the information.

Website: http://koreapharma.co.kr

Basic Information
Total Employees:
Purchase the Korea Pharma Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Korea Pharma Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Korea Pharma Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Korea Pharma Co.,Ltd. report to view the information.
Incorporation Date:
December 24, 1985
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
(주)한국파마
Company Performance
Financial values in the chart are available after Korea Pharma Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
4.6%
Total operating revenue
1.09%
Operating profit (EBIT)
-91.72%
EBITDA
-83.62%
Net Profit (Loss) for the Period
-99.81%
Total assets
-6.26%
Total equity
19.34%
Operating Profit Margin (ROS)
-49.45%
Net Profit Margin
-54.02%
Return on Equity (ROE)
-74.83%
Debt to Equity Ratio
-42.65%
Quick Ratio
-1.14%
Cash Ratio
-0.97%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?